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The interrelationship between pregnancy,
venous thromboembolism, and thyroid
disease: a hypothesis-generating review
Stine Linding Andersen1,2* , Kasper Krogh Nielsen1,2 and Søren Risom Kristensen1,2
Abstract
Pregnancy induces physiological changes that affect the risk of thrombosis and thyroid disease. In this hypothesis-
generating review, the physiological changes in the coagulation system and in thyroid function during a normal
pregnancy are described, and the incidence of venous thromboembolism (VTE) and thyroid disease in and after a
pregnancy are compared and discussed. Furthermore, evidence regarding the association between thyroid disease
and VTE in non-pregnant individuals is scrutinized. In conclusion, a normal pregnancy entails hormonal changes,
which influence the onset of VTE and thyroid disease. Current evidence suggests an association between thyroid
disease and VTE in non-pregnant individuals. This review proposes the hypothesis that maternal thyroid disease
associates with VTE in pregnant women and call for future research studies on this subject. If an association exists
in pregnant women specifically, such findings may have clinical implications regarding strategies for thyroid
function testing and potential thromboprophylaxis in selected individuals.
Keywords: Pregnancy, Postpartum, Coagulation, Thrombosis, Thyroid
Introduction
A normal pregnancy comprises a series of physiological
changes, which challenge the diagnosis of maternal dis-
eases and affect the incidence of various diseases in and
after a pregnancy. Changes in the coagulation system
during a pregnancy include an increase in the levels of
coagulation factors and fibrinolytic inhibitors, making
pregnancy a hypercoagulable and hypofibrinolytic state.
Thus, the risk of venous thromboembolism (VTE), i.e.
deep venous thrombosis (DVT) and the complicating
pulmonary embolism, increases gradually during preg-
nancy and peaks in the early postpartum period [1–3].
Furthermore, the anatomic changes during a pregnancy
contribute to the risk as evidenced by the increased
incidence of proximal left-sided VTE in pregnant
women. Also, the function of the thyroid gland is con-
siderably altered in pregnancy to ensure supply of thy-
roid hormone to the fetus. A predominant effect on
thyroid function is mediated via the pregnancy hormone
human chorionic gonadotropin (hCG), which stimulates
the thyroid gland to an increased production of thyroid
hormone [4]. Moreover, the changes in the immune sys-
tem in and after a pregnancy may influence the onset of
autoimmune thyroid disease [5–7]. Consequently, preg-
nancy entails numerous physiological changes capable of
altering the coagulation system and the function of the
thyroid gland. Adding to this, increasing evidence has in-
dicated an association between abnormal thyroid func-
tion and abnormalities in the coagulation system in non-
pregnant individuals [8–10].
We speculated on the possible interrelationship be-
tween pregnancy, VTE, and thyroid disease and per-
formed a hypothesis-generating review on this subject.
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More specifically, we aimed to provide an overview of
the physiological changes associated with a normal preg-
nancy in the coagulation system and in thyroid function
and to describe the occurrence of VTE and thyroid dis-
ease in and after pregnancy. Furthermore, we aimed to
describe the association between thyroid disease and
VTE in non-pregnant individuals and to discuss possible
mechanisms of their interaction in pregnancy. The re-
view calls for future research studies that investigate the
proposed hypothesis in pregnant women specifically. If
an association exists, this could have clinical implications
regarding strategies for thyroid function testing and
thromboprophylaxis in selected individuals.
The coagulation system in pregnancy
Hemostasis consists of primary hemostasis, the co-
agulation system, and the fibrinolytic system. The
primary hemostasis will establish a platelet plug.
When the endothelial layer is damaged, von Willeb-
rand factor (vWF) will bind to the subendothelial
collagen structures enabling platelets to adhere, get
activated and to form a platelet plug [11]. The sec-
ondary hemostasis results in the formation of a fi-
brin network to stabilize the plug (Fig. 1). It is
activated via tissue factor (TF), which is present in
the sub-endothelial layers [12]. TF forms a complex
with coagulation factor VIIa, which in turn activates
factors X and IX leading to the formation of throm-
bin (factor IIa) [12, 13]. Thrombin gives rise to a
powerful positive feedback activation of factors V,
VIII, and XI. Factors Va and VIIIa are cofactors for
factors Xa and IXa, respectively, and the feedback
mechanisms increase the enzyme activities more
than 1000 times [13]. This gives rise to a large for-
mation of thrombin that cleaves fibrinogen into fi-
brin successively forming a fibrin network. Factor
XIIIa, activated by thrombin, catalyzes the formation
of covalent bonds between the fibrin monomers that
strengthen the plug [14, 15].
The activity of the coagulation system is balanced by
endogenous anticoagulants (Fig. 1). Tissue factor path-
way inhibitor (TFPI) in complex with factor Xa inacti-
vates the TF/factor VIIa-complex [16]. Antithrombin
(AT) inactivates thrombin and factors IXa, Xa, and XIa
[17]. Finally, activated protein C (PCa) will, in complex
with Protein S (PS), inactivate factors Va and VIIIa [18].
The fibrin network can be dissolved by the fibrinolytic
system (Fig. 1). Mainly tissue-type plasminogen activator
(t-PA), but also urokinase-type plasminogen activator
(u-PA), can activate plasminogen to plasmin, which is an
enzyme that catalyzes the degradation of fibrin to
smaller parts, among others D-dimer [15]. t-PA and u-
PA can be inhibited by plasminogen activator inhibitor-1
(PAI-1). During pregnancy, placenta produces another
inhibitor, the so-called plasminogen activator inhibitor-2
(PAI-2) [15].
During pregnancy several changes lead to a procoagu-
lant condition (Fig. 1), which is probably an evolutionary
adaptation to protect against hemorrhage during the in-
nate traumatic nature of giving birth. Especially the
levels of vWF, fibrinogen, and factor VIII increase [19,
20], thus, they gradually increase from the first trimester
to reach 2–3 times the non-pregnant level at delivery,
and the levels normalize again a few weeks after birth of
the child. The levels of factors VII and IX also increase,
reaching levels of 30–50% above the non-pregnant state
at delivery, whereas factors II, V, X, and XI are essen-
tially unaltered [20]. In the anticoagulant system, the
most marked change during pregnancy is a lowering of
protein S which occurs early in pregnancy and the level
of this anticoagulant is more than halved in second and
third trimester [20–22]. In the fibrinolytic system, the
inhibitors PAI-1 and PAI-2 gradually increase from the
second trimester making pregnancy a hypofibrinolytic
state [23, 24]. As a result of these changes, the routine
laboratory analyses such as the activated partiel
thromboplastin time (APTT) and prothrombin time
(PT) may shorten slightly during pregnancy and postpar-
tum, whereas D-dimer increases considerably, especially
during the second and third trimester and immediately
postpartum [20, 25].
VTE in and after a pregnancy
Due to the physiological changes associated with preg-
nancy, the risk of VTE in pregnant women is 4–6-
fold increased [1]. Besides the changes in the
hemostatic system, the distension of the uterus may
cause a compression on the veins in pelvis and most
pregnancy-related DVTs are localized in the left lower
extremity [26]. In addition, personal factors such as
obesity, the presence of thrombophilia, age, comorbid-
ities (e.g. inflammatory bowel disease) and complica-
tions during pregnancy (e.g. preeclampsia, gestational
diabetes, and caesarean section) increase the risk [2,
27]. The incidence has been calculated in some re-
views to 1.1–1.2 per 1000 deliveries [2, 3], but with a
substantial variation between studies depending on
the populations. It is a characteristic that the inci-
dence of DVT in pregnancy varies with gestational
age [1, 2]. Thus, the incidence is steadily increasing
in pregnancy with increasing gestational age and
peaks around birth of the child (Fig. 2, upper part).
In the postpartum period, the incidence of DVT is
high immediately after birth of the child and declines
within the first and second postpartum month reach-
ing non-pregnant levels in the third month (Fig. 2,
upper part).
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Thyroid function in pregnancy
Thyroid diseases are common endocrine disorders and
part of the chronic disease burden in pregnant women
[28]. Thyroid hormones are important developmental
factors and play a crucial role during fetal brain develop-
ment [29]. The fetal thyroid gland is increasingly able to
synthesize thyroid hormones from mid-pregnancy, but
adequate levels of maternal thyroid hormones is import-
ant to ensure supply of thyroid hormones to the fetus
throughout the pregnancy [30, 31]. The physiological
changes during a normal pregnancy affect the thyroid
gland and challenge the evaluation of maternal thyroid
function in pregnancy [4]. As in non-pregnant individ-
uals, thyroid function is assessed from the measurement
of thyroid stimulating hormone (TSH) and the thyroid
hormones thyroxine (T4) and triiodothyronine (T3). The
majority of circulating T4 and T3 is protein-bound and
predominantly bound to thyroxine binding globulin
(TBG). T4 and T3 can be evaluated from the measure-
ment of the total or the free thyroid hormone concentra-
tion. As in non-pregnant individuals, overt
hyperthyrodism and hypothyroidism are defined by TSH
and T3/T4 outside the reference ranges, whereas sub-
clinical disease is characterized by isolated abnormalities
in TSH. However, non-pregnant reference ranges cannot
be used for the evaluation of maternal thyroid function
in pregnancy, and pregnancy specific reference ranges
should preferably be established and used [32].
Much emphasis has been on the use of trimester spe-
cific reference ranges, but more recent data indicate that
Fig. 1 A simplified overview of the secondary hemostasis including the main alterations in pregnancy. Factors that considerably change in
pregnancy are marked in bold (protein S (PS) decreases, others increase), and anticoagulants are marked in italic. See text for details. AT;
antithrombin, PAI-1; plasminogen activator inhibitor-1, PAI-2: plasminogen activator inhibitor-2, PCa; activated protein C, TF: tissue factor, TFPI;
tissue factor pathway inhibitor, t-PA; tissue-type plasminogen activator
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maternal TSH is dynamic even within the first trimester
of pregnancy [33, 34]. Firstly, the rising estrogen levels
in early pregnancy cause an increase in TBG via the ef-
fect of estrogen on the liver. This in turn is followed by
a concomitant gradual increase in maternal total T4 and
total T3 concentrations. This physiological alteration in
the total thyroid hormone concentrations has led to the
use of free thyroid hormone measurements in many
settings. However, automatic immunoassays used in
clinical laboratories for the measurement of free T4 and
free T3 are indirect methods with no initial separation
of free and protein-bound hormone. Thus, the methods
are prone to alterations in binding proteins, also in preg-
nant women, and variation between different assays may
be seen [34]. Secondly, hCG shows structural similarities
with TSH enabling it to stimulate the thyroid gland to
Fig. 2 Illustration of the incidence rates of venous thromboembolism, hyperthyroidism, and hypothyroidism in and around pregnancy. The
illustration is made using data from Danish nationwide investigations [1, 6, 7]
Andersen et al. Thyroid Research           (2021) 14:12 Page 4 of 10
an increased production of thyroid hormones. This
mechanism tends to suppress TSH in early pregnancy
and this physiological effect is most pronounced in the
last part of the first trimester, when the hCG concentra-
tion peaks (Fig. 3). A third physiological mechanism is in
play in the early pregnancy. The type 3 deiodinase
(DIO3) is an enzyme that catalyzes the conversion of T4
to reverse T3 and T3 to T2, thus, inactivating thyroid
hormones [35]. This enzyme is expressed in placenta
from the early pregnancy and is thought to protect the
fetus against excessive transport of thyroid hormones
[36, 37]. The activity of the enzyme tends to increase
maternal TSH in the early pregnancy (Fig. 3), and mater-
nal TSH in the first trimester may reflect the balance be-
tween the DIO3 activity and the hCG effect [4, 33, 34].
Thus, TSH is initially at pre-pregnancy levels followed
by a gradual decline with increasing gestational age
within the first trimester of pregnancy (Fig. 3) [33].
Thyroid disease in and after a pregnancy
Thyroid diseases in women of fertile age are predomin-
antly of autoimmune origin [38, 39]. In addition to the
physiological alterations in maternal thyroid function,
the pregnant state affects the immune system. There is a
characteristic immune suppression in pregnancy to allow
for the development of the fetus and subsequently an
immune rebound after birth of the child. Such alter-
ations may affect the development of autoimmune dis-
eases in and after pregnancy (Fig. 2, lower parts) [6, 7].
Autoimmune thyroid diseases are characterized by the
presence of thyroid autoantibodies. Autoimmune hyper-
thyroidism, also known as Graves’ disease (GD), is asso-
ciated with TSH-receptor antibodies (TRAb) [39],
whereas autoimmune hypothyroidism, also known as
Hashimotos’ thyroiditis, is associated with thyroid perox-
idase (TPO) and thyroglobulin (Tg) antibodies [38]. Thy-
roid autoimmunity tends to diminish during pregnancy
with a decline in the incidence of autoimmune thyroid
disease, while an immune rebound mechanism after
birth may trigger onset of disease (Fig. 2, lower parts) [6,
7]. The hyperthyroidism of GD should be distinguished
from gestational hyperthyroidism caused by hCG in
early pregnancy and from hyperthyroidism as part of
postpartum thyroiditis after birth of the child [4]. Gesta-
tional hyperthyroidism and hyperthyroidism as part of
postpartum thyroiditis are transient disorders and
should typically not be treated with antithyroid drugs
[32]. The diagnosis may be difficult, however, the pres-
ence of TRAb and persistent hyperthyroidism favor a
diagnosis of GD [32].
Thyroid disease and VTE in non-pregnant
individuals
Thyroid hormones have many physiological effects and
regulate growth, development, and metabolism [29, 30].
It has long been considered whether alterations in the
levels of thyroid hormones could disturb the coagulation
system. Historically, it has been the view that an in-
creased level of thyroid hormones is associated with a
procoagulant condition and vice versa for a low level of
thyroid hormones. One of the earliest investigations was
published in 1965 by Simone et al. who showed high
Fig. 3 Illustration of the upper (97.5 percentile) and lower (2.5
percentile) reference limit with 95% confidence interval for maternal
thyroid stimulating hormone (TSH) in early pregnancy stratified by
weeks of pregnancy. Data are from a regional Danish investigation
in which maternal TSH was assessed using different biochemical
methods (filled circles: Cobas 8000, Roche Diagnostics, open circles:
ADVIA Centaur XPT, Siemens Healthineers) [34]
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and low levels of some coagulation factors in 25 hyper-
thyroid patients and 7 hypothyroid patients, respectively
[40]. Several studies have later been performed on this
subject, and reviews have drawn the same conclusion
[8–10]. In 2012, Stuijver et al. concluded in a systematic
review and meta-analysis that hyperthyroidism was asso-
ciated with a procoagulant, hypofibrinolytic condition
with increased levels of factors VIII and IX, fibrinogen,
vWF, and PAI-1 [8], and these changes actually resemble
to some extent the physiological changes during preg-
nancy. Prior to this report, a systematic review published
in 2007 by Squizzato et al. reported that changes in
hypothyroidism was in the opposite direction [9].
In accordance with these findings, hyperthyroidism
has been associated with an increased risk of VTE in
large observational studies from different countries
(Table 1) [41–47]. The studies differed in design and
method of exposure assessment, thus, some studies re-
lied on actual measurement of thyroid function parame-
ters in blood samples, whereas others used an indirect
measure of exposure from registration of hospital diag-
noses. Consequently, it varied between the studies
whether information on the subtype of hyperthyroidism
was included, e.g. whether it was of autoimmune origin
as part of GD. These methodological differences may
challenge the direct comparison of individual studies,
however, more than half of the studies consistently re-
ported an association between hyperthyroidism and
VTE. In support of such an association, some studies
also evaluated the association between thyroid hormone
levels and outcome of VTE (Table 1) [48–51]. In a
population-based cohort study, Lerstad et al. found no
association between levels of TSH within the normal
range and future development of VTE during 8 years of
follow-up, whereas individuals with low and high TSH
had a slightly higher risk [48]. Debeij et al. showed in a
cohort study and later in a case-control study that the
risk of VTE increased with increasing free T4 levels,
even within the upper end of the reference interval [49,
50]. The case-control study confirmed that vWF, factors
VIII and IX, and fibrinogen increased gradually as free
T4 increased, and that the concentration of these pro-
teins, except for fibrinogen, were low at low free T4
levels [49].
In line with these latter findings regarding low
levels of thyroid hormones, reports on outcomes of
hypothyroidism have predominantly described an in-
creased risk of bleeding in these patients [52], and a
quite substantial bleeding risk during treatment with
warfarin [53]. Several reports, mainly case-reports,
Table 1 Observational studies on the association between thyroid function and outcomes of venous thromboembolism (deep
venous thrombosis and/or pulmonary embolism) in non-pregnant individuals
Author Yeara Country Design Population (n) Exposure assessment Type of exposure Associationb
Hyperthyroidism
Dekkers et al. [41] 2017 Denmark Cohort 932,913 Hospital diagnoses Unspecified ↑
Segna et al. [42] 2016 Schwitzerland Cohort 561 Biochemical Subclinical ↓
Zöller et al. [43] 2012 Sweden Cohort 535,538 Hospital diagnoses Unspecified ↑
Ramagopalan et al. [44] 2011 United Kingdom Cohort 4,310,042 Hospital diagnoses Unspecified ↑
Lin et al. [45] 2010 Taiwan Case-cohort 53,418 Hospital diagnoses Unspecified ↑
Danescu et al. [46] 2009 United States Cohort 908,805,000 Hospital diagnoses Unspecified –
Squizzato et al. [47] 2007 Italy Cross-sectional 150 Biochemical Overt and subclinical –
Hypothyroidism
Segna et al. [42] 2016 Schwitzerland Cohort 561 Biochemical Subclinical –
Zöller et al. [43] 2012 Sweden Cohort 535,538 Hospital diagnoses Unspecified ↑
Ramagopalan et al. [44] 2011 United Kingdom Cohort 4,869,188 Hospital diagnoses Unspecified ↑
Danescu et al. [46] 2009 United States Cohort 928,324,000 Hospital diagnoses Unspecified ↑
Squizzato et al. [47] 2007 Italy Cross-sectional 150 Biochemical Overt and subclinical ↑
Thyroid homone levels
Lerstad et el [48]. 2015 Norway Cohort 11,962 Biochemical TSH ↑
Debeij et al. [49] 2014 Netherlands Case-control 5003 Biochemical TSH and free T4 ↑
Debeij et al. [50] 2012 Norway Cohort 1991 Biochemical TSH and free T4 ↑
van Zaane et al. [51] 2009 Netherlands Case-control 569 Biochemical TSH, free T4, total T3 ↑
Abbreviations: TSH Thyroid stimulating hormone, T4 Thyroxine, T3 Triiodothyronine
aYear of publication
bIndicates whether an association between the type of exposure and outcome of venous thromboembolism was observed, see text for details. ↑ higher risk, ↓
lower risk, − no association
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have described an acquired von Willebrand disease
(aVWD), i.e. a low level of vWF, in hypothyroid indi-
viduals [54]. A study of consecutive hypothyroid pa-
tients found that one third of these patients had
aVWD, and this may be the main cause of bleeding
[55]. The condition appears to be reversible as treat-
ment with Levothyroxine may normalize levels of
vWF in a substantial part of the patients [55]. In con-
trast to this general notion on hypothyroidism and
the coagulation system, there are also reports evaluat-
ing the risk of VTE in hypothyroid individuals (Table
1) [42–44, 46, 47]. Like the observational findings re-
garding hyperthyroidism, most of these studies re-
ported an increased risk of VTE associated with
hypothyroidism. All studies were observational in de-
sign and attempts were made to include potential
confounders in multivariate analyses. However,
hypothyroidism and VTE share some of the same risk
factors, e.g. obesity, which may influence results [56,
57]. On the other hand, smoking which is a risk fac-
tor for VTE, seems to protect against autoimmune
hypothyroidism [58, 59], illustrating the complexity in
the evaluation of various risk factors for VTE. An-
other consideration is on the autoimmune origin of
thyroid diseases, and one may speculate on the role
of abnormal thyroid function as opposed to thyroid
autoimmunity per se. Autoimmune diseases are a
heterogenous group of disorders with multifactorial
etiology. Many autoimmune diseases show female pre-
dominance and many of the diseases affect women of
fertile age [60]. Studies looking at a spectrum of auto-
immune diseases found an increased risk of VTE in
all the autoimmune disorders that they investigated
[43], suggesting that autoimmune mechanisms may
play a role also in the association between thyroid
disease and VTE. Adding to this, autoimmune thyroid
diseases overlap with other autoimmune diseases in-
cluding endocrine disorders (type 1 diabetes, Addi-
son’s disease) and rheumatological disorders (systemic
lupus erythematosus, rheumatoid arthritis) [61]. One
may speculate on underlying shared genetic risk fac-
tors for thrombosis and on underlying pathophysio-
logical alterations in the immune system that cause a
prothrombotic condition. A key mechanism in many
autoimmune disorders is the presence of autoanti-
bodies, and the autoantibodies characteristic of auto-
immune thyroid disease, e.g. TPO-antibodies, are
more commonly found in other autoimmune diseases
[61]. Antiphospholipid antibodies and platelet anti-
bodies are some of the main autoantibodies described
in relation to autoimmune disorders, which may
present with thrombosis and/or bleeding symptoms
(e.g. antiphospholipid syndrome and idiopathic (or
immune) thrombocytopenic purpura) [62, 63]. A
possible overlap between these autoimmune disorders
and autoantibodies with autoimmune thyroid diseases
is an interesting pathophysiological thought and a
relevant topic for future research.
In summary, hyperthyroidism in non-pregnant individ-
uals is a procoagulant condition associated with an in-
creased risk of VTE. Hypothyroidism may be associated
with a lower activity in the coagulation system and
therefore a tendency to increased risk of bleeding but is
also associated with an increased risk of VTE.
Thyroid disease and VTE in pregnant individuals
Moving from non-pregnant to pregnant individuals, it is
relevant to consider if similar associations between thy-
roid disease and VTE exist in pregnancy. As described,
there are numerous physiological alterations in and
around pregnancy that affect maternal thyroid function
and the function of the coagulation system. No original
studies have yet investigated the interrelationship be-
tween pregnancy, VTE, and thyroid disease, but the inci-
dence of the diseases in and after a pregnancy have been
considered separately [1, 6, 7]. In both disorders, preg-
nancy and the postpartum period seem to have a strong
influence on the onset of disease, but the timing of the
incidence peak varies (Fig. 2). The incidence of VTE is
increasing in pregnancy and peaks just around birth of
the child and in the early postpartum weeks. On the
other hand, the incidence of hyperthyroidism and
hypothyroidism declines with the length of pregnancy
and peaks 4–6months postpartum (Fig. 2). These inci-
dence data emerged from large population-based
register-studies using different cohorts, and thyroid dis-
ease and VTE were not evaluated in the same individ-
uals. However, each study included enough women to
provide estimates stratified by short time periods within
and after a pregnancy, and the figures (Fig. 2) provide
clues on the pattern of incidence variation for each dis-
order in relation to the pregnancy period. It should be
noted that the identification of disease using such de-
sign, relied on hospital diagnoses and redeemed pre-
scriptions of drugs. Thus, the onset of disease is a proxy
defined from these data, and actual onset may have pre-
ceded the date of diagnosing or initiation of treatment,
especially for thyroid diseases, which typically present
less acute [6, 7].
We can only speculate on possible mechanisms behind
an interplay between thyroid disease and VTE in preg-
nancy. Obviously, the incidence of the diseases in and
around pregnancy are not changing in parallel (Fig. 2),
but from the findings in non-pregnant individuals, we
speculate whether abnormalities in maternal thyroid
function in pregnancy could exacerbate the physiologic-
ally altered coagulation function in pregnant women.
Thyroid hormones regulate the transcription of proteins
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including the coagulation proteins [64]. Evidence from
non-pregnant individuals indicate that thyroid hormones
may cause elevated coagulation factors in hyperthyroid
patients [8]. Furthermore, thyroid hormone alterations
may affect the synthesis of sex hormones, and elevated
concentrations of estradiol and the sex-hormone-
binding-globulin may be seen in hyperthyroidism [65].
This alteration may further enhance the effect of estra-
diol on the coagulation system.
In summary, an association between thyroid disease
and VTE in pregnant women seems biologically plaus-
ible, particularly regarding hyperthyroidism. As in non-
pregnant individuals, autoimmune mechanisms could
also play a role and shared environmental risk factors
between thyroid disease and VTE should be considered
as part of the hypothesis.
Clinical implications
Our aim with the present review was to describe the hy-
pothesis of an association between thyroid disease and VTE
in pregnancy, specifically, and to enhance future scientific
work on this subject. If an association is established, a per-
spective of prevention and clinical implications will follow.
Clinical uncertainties exist regarding both disorders. For
thyroid disease in pregnancy, the benefits and risks of
routine testing of thyroid function are not clarified, and a
risk-based screening is currently recommended [32]. Con-
sidering treatment of thyroid disease in pregnancy, overt
hyper- and hypothyroidism should be treated to prevent
maternal and fetal complications, but for subclinical hyper-
thyroidism there is no recommendation of treatment and
for subclinical hypothyroidism, the indication for treatment
depends on the combined assessment of TSH levels and
the presence of TPO-antibodies [32]. From studies in non-
pregnant individuals it seems uncertain whether associa-
tions with VTE primarily occur in overt or also in subclin-
ical thyroid disease [42, 48], and the distinction between
subtypes of thyroid function abnormalities is an important
focus of future research in pregnant and in non-pregnant
individuals. For the management of VTE in pregnant
women, the main clinical decision is on the indication for
thromboprophylaxis [66]. This decision is based upon an
assessment of individual risk factors including the presence
of thrombophilia and other medical conditions. If an associ-
ation between thyroid disease and VTE in pregnancy is
established, a future clinical perspective is whether women
with thyroid disease are considered at high risk for throm-
bosis and would benefit from thromboprophylaxis in the
pregnancy, especially as an additional risk factor in women
with other risk factors.
Conclusions
Substantial evidence suggests an association between ab-
normal thyroid function and abnormalities in the
coagulation system in non-pregnant individuals, and an
increased risk of VTE has been proposed in hyperthyroid
and hypothyroid patients. Thyroid disease and VTE are
a matter of concern in pregnant women, and the physio-
logical changes in pregnant women affect the incidence
of the disorders. To our knowledge, no studies have yet
investigated the interrelationship between pregnancy,
VTE, and thyroid disease. Future scientific work should
enhance our understanding of a potential association be-
tween thyroid disease and VTE in pregnant women spe-
cifically. Expanding future work to include the
biochemical assessment of thyroid hormone parameters,
autoantibodies, coagulation proteins, and sex-hormones
could shed light on the relationship, and the potential
role of autoimmune mechanisms and environmental fac-
tors should preferably also be considered.
Abbreviations
APTT: Activated partiel thromboplastin time; aVWD: Acquired von Willebrand
disease; DIO3: Type 3 deiodinase; DVT: Deep venous thrombosis; GD: Graves’
disease; hCG: Human chorionic gonadotropin; PCa: Activated protein C; PAI-
1: Plasminogen activator inhibitor-1; PAI-2: Plasminogen activator inhibitor-2;
PS: Protein S; PT: Prothrombin time; TBG: Thyroxine binding globulin;
TF: Tissue factor; Tg: Thyroglobulin; t-PA: Tissue-type plasminogen activator;
TPO: Thyroid peroxidase; TRAb: TSH-receptor antibodies; TSH: Thyroid
stimulating hormone; T3: Triiodothyronine; T4: Thyroxine; u-PA: Urokinase-





SLA and SRK conceptualized the study. All authors contributed to the writing






Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analysed during the current study.
Declarations





The author declares that she has no competing interests.
Received: 16 March 2021 Accepted: 26 April 2021
References
1. Virkus RA, Leth Løkkegaard EC, Bergholt T, Mogensen U, Langhoff-Roos J,
Lidegaard Ø. Venous thromboembolism in pregnant and puerperal women
in Denmark 1995-2005; a national cohort study. Thromb Haemost. 2011;
106(2):304–9. https://doi.org/10.1160/TH10-12-0823.
Andersen et al. Thyroid Research           (2021) 14:12 Page 8 of 10
2. Parunov LA, Soshitova NP, Ovanesov MV, Panteleev MA, Serebriyskiy II.
Epidemiology of venous thromboembolism (VTE) associated with
pregnancy. Birth Defects Res C Embryo Today. 2015;105(3):167–84. https://
doi.org/10.1002/bdrc.21105.
3. Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic
review and meta-analysis of the epidemiology and burden of venous
thromboembolism among pregnant women. Int J Gynaecol Obstet Off
organ Int Fed Gynaecol Obstet. 2016;132(1):4–10. https://doi.org/10.1016/j.
ijgo.2015.06.054.
4. Laurberg P, Andersen SL. Endocrinology in pregnancy: Pregnancy and the
incidence, diagnosing and therapy of graves’ disease. Eur J Endocrinol.
2016;175(5):R219–30. https://doi.org/10.1530/EJE-16-0410.
5. Weetman AP. Immunity, thyroid function and pregnancy: molecular
mechanisms. Nat Rev. 2010;6:311–8.
6. Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence
fluctuates widely in and around pregnancy and is at variance with some
other autoimmune diseases: a Danish population-based study. J Clin
Endocrinol Metab. 2015;100(3):1164–71. https://doi.org/10.1210/jc.2014-3588.
7. Andersen SL, Carle A, Olsen J, Laurberg P. Hypothyroidism incidence in and
around pregnancy: a Danish nationwide study. Eur J Endocrinol. 2016;175(5):
387–93. https://doi.org/10.1530/EJE-16-0446.
8. Stuijver DJF, van Zaane B, Romualdi E, Brandjes DPM, Gerdes VEA, Squizzato
A. The effect of hyperthyroidism on procoagulant, anticoagulant and
fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost.
2012;108(6):1077–88. https://doi.org/10.1160/TH12-07-0496.
9. Squizzato A, Romualdi E, Büller HR, Gerdes VEA. Clinical review: thyroid
dysfunction and effects on coagulation and fibrinolysis: a systematic review.
J Clin Endocrinol Metab. 2007;92(7):2415–20. https://doi.org/10.1210/jc.2007-
0199.
10. Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the
coagulation system and its clinical consequences. J Thromb Haemost. 2018;
16(4):634–45. https://doi.org/10.1111/jth.13970.
11. Karampini E, Bierings R, Voorberg J. Orchestration of primary hemostasis by
platelet and endothelial lysosome-related organelles. Arterioscler Thromb
Vasc Biol. 2020;40(6):1441–53. https://doi.org/10.1161/ATVBAHA.120.314245.
12. D’Alessandro E, Posma JJN, Spronk HMH, Ten Cate H. Tissue factor (:factor
VIIa) in the heart and vasculature: more than an envelope. Thromb Res.
2018;168:130–7. https://doi.org/10.1016/j.thromres.2018.06.020.
13. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin
generation. Semin Thromb Hemost. 2006;32(S 1):32–8. https://doi.org/10.1
055/s-2006-939552.
14. Bagoly Z, Katona E, Muszbek L. Factor XIII and inflammatory cells. Thromb
Res. 2012;129:S77–81. https://doi.org/10.1016/j.thromres.2012.02.040.
15. Memtsas VP, Arachchillage DRJ, Gorog DA. Role, laboratory assessment and
clinical relevance of fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial
and Venous Thrombosis. Int J Mol Sci. 2021;22:3.
16. Broze GJJ, Girard TJ. Factor V, tissue factor pathway inhibitor, and East Texas
bleeding disorder. J Clin Invest. 2013;123(9):3710–2. https://doi.org/10.1172/
JCI71220.
17. Bravo-Pérez C, Vicente V, Corral J. Management of antithrombin deficiency:
an update for clinicians. Expert Rev Hematol. 2019;12(6):397–405. https://doi.
org/10.1080/17474086.2019.1611424.
18. Alshaikh NA, Rosing J, Thomassen MCLGD, Castoldi E, Simioni P, Hackeng
TM. New functional assays to selectively quantify the activated protein C-
and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
J Thromb Haemost. 2017;15(5):950–60. https://doi.org/10.1111/jth.13657.
19. Sánchez-Luceros A, Meschengieser SS, Marchese C, Votta R, Casais P, Woods
AI, et al. Factor VIII and von Willebrand factor changes during normal
pregnancy and puerperium. Blood Coagul fibrinolysis an Int J Haemost
Thromb. 2003;14(7):647–51. https://doi.org/10.1097/00001721-200310000-
00005.
20. Szecsi PB, Jørgensen M, Klajnbard A, Andersen MR, Colov NP, Stender S.
Haemostatic reference intervals in pregnancy. Thromb Haemost. 2010;
103(4):718–27. https://doi.org/10.1160/TH09-10-0704.
21. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5-6):
409–14. https://doi.org/10.1016/j.thromres.2004.08.004.
22. Kristoffersen AH, Petersen PH, Røraas T, Sandberg S. Estimates of within-
subject biological variation of protein C, Antithrombin, protein S free,
protein S activity, and activated protein C resistance in pregnant women.
Clin Chem. 2017;63(4):898–907. https://doi.org/10.1373/clinchem.2016.2
65900.
23. Kjellberg U, Andersson NE, Rosén S, Tengborn L, Hellgren M. APC resistance
and other haemostatic variables during pregnancy and puerperium.
Thromb Haemost. 1999;81(4):527–31.
24. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin
Haematol. 2003;16(2):153–68. https://doi.org/10.1016/S1521-6926(03)00021-5.
25. Gong J-M, Shen Y, He Y-X. Reference intervals of routine coagulation assays
during the pregnancy and Puerperium period. J Clin Lab Anal. 2016;30(6):
912–7. https://doi.org/10.1002/jcla.21956.
26. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the
puerperium: a meta-analysis of the period of risk and the leg of
presentation. Obstet Gynecol Surv. 1999;54(4):265–71. https://doi.org/10.1
097/00006254-199904000-00023.
27. Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, et al. Risk
factors for first venous thromboembolism around pregnancy: a population-
based cohort study from the United Kingdom. Blood. 2013;121(19):3953–61.
https://doi.org/10.1182/blood-2012-11-469551.
28. Jolving LR, Nielsen J, Kesmodel US, Nielsen RG, Beck-Nielsen SS, Norgard
BM. Prevalence of maternal chronic diseases during pregnancy - a
nationwide population based study from 1989 to 2013. Acta Obstet
Gynecol Scand. 2016;95(11):1295–304. https://doi.org/10.1111/aogs.13007.
29. Bernal J, Nunez J. Thyroid hormones and brain development. Eur J
Endocrinol. 1995;133(4):390–8. https://doi.org/10.1530/eje.0.1330390.
30. de Escobar GM, Obregon MJ, del Rey FE. Maternal thyroid hormones early
in pregnancy and fetal brain development. Best Pract Res Endocrinol Metab.
2004;18(2):225–48. https://doi.org/10.1016/j.beem.2004.03.012.
31. Andersen SL, Olsen J, Laurberg P. Foetal programming by maternal thyroid
disease. Clin Endocrinol. 2015;83(6):751–8. https://doi.org/10.1111/cen.12744.
32. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017
guidelines of the American Thyroid Association for the diagnosis and
Management of Thyroid Disease during Pregnancy and the postpartum.
Thyroid. 2017;27(3):315–89. https://doi.org/10.1089/thy.2016.0457.
33. Laurberg P, Andersen SL, Hindersson P, Nohr EA, Olsen J. Dynamics and
predictors of serum TSH and fT4 reference limits in early pregnancy: a study
within the Danish National Birth Cohort. J Clin Endocrinol Metab. 2016;
101(6):2484–92. https://doi.org/10.1210/jc.2016-1387.
34. Andersen SL, Christensen PA, Knøsgaard L, Andersen S, Handberg A,
Hansen AB, et al. Classification of thyroid dysfunction in pregnant women
differs by analytical method and type of thyroid function test. J Clin
Endocrinol Metab. 2020;105:1–11.
35. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry,
cellular and molecular biology, and physiological roles of the iodothyronine
selenodeiodinases. Endocr Rev. 2002;23(1):38–89. https://doi.org/10.1210/
edrv.23.1.0455.
36. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, et al.
A longitudinal study of serum TSH, and total and free iodothyronines
during normal pregnancy. Acta Endocrinol. 1982;101(4):531–7. https://doi.
org/10.1530/acta.0.1010531.
37. Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS. Maternal to
fetal thyroxine transmission in the human term placenta is limited by inner
ring deiodination. J Clin Endocrinol Metab. 1996;81(6):2247–9. https://doi.
org/10.1210/jcem.81.6.8964859.
38. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al.
Epidemiology of subtypes of hypothyroidism in Denmark. Eur J Endocrinol.
2006;154(1):21–8. https://doi.org/10.1530/eje.1.02068.
39. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al.
Epidemiology of subtypes of hyperthyroidism in Denmark: a population-
based study. Eur J Endocrinol. 2011;164(5):801–9. https://doi.org/10.1530/
EJE-10-1155.
40. Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid
dysfunction. N Engl J Med. 1965;273(20):1057–61. https://doi.org/10.1056/
NEJM196511112732001.
41. Dekkers OM, Horváth-Puhó E, Cannegieter SC, Vandenbroucke JP, Sørensen
HT, Jørgensen JOL. Acute cardiovascular events and all-cause mortality in
patients with hyperthyroidism: a population-based cohort study. Eur J
Endocrinol. 2017;176(1):1–9. https://doi.org/10.1530/EJE-16-0576.
42. Segna D, Méan M, Limacher A, Baumgartner C, Blum MR, Beer JH, et al.
Association between thyroid dysfunction and venous thromboembolism in
the elderly: a prospective cohort study. J Thromb Haemost. 2016;14(4):685–
94. https://doi.org/10.1111/jth.13276.
43. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in
patients with autoimmune disorders: a nationwide follow-up study from
Andersen et al. Thyroid Research           (2021) 14:12 Page 9 of 10
Sweden. Lancet. 2012;379(9812):244–9. https://doi.org/10.1016/S0140-673
6(11)61306-8.
44. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of
venous thromboembolism in people admitted to hospital with selected
immune-mediated diseases: record-linkage study. BMC Med. 2011;9(1):1.
https://doi.org/10.1186/1741-7015-9-1.
45. Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism
among patients with hyperthyroidism: a 5-year follow-up study. J
Thromb Haemost. 2010;8(10):2176–81. https://doi.org/10.1111/j.1538-783
6.2010.03993.x.
46. Danescu LG, Badshah A, Danescu SC, Janjua M, Marandici AM, Matta F, et al.
Venous thromboembolism in patients hospitalized with thyroid dysfunction.
Clin Appl Thromb. 2009;15(6):676–80. https://doi.org/10.1177/107602960933
6856.
47. Squizzato A, Romualdi E, Piantanida E, Gerdes VEA, Büller HR, Tanda M, et al.
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-
sectional study. Thromb Haemost. 2007;97(5):803–6.
48. Lerstad G, Enga KF, Jorde R, Brodin EE, Svartberg J, Brækkan SK, et al.
Thyroid function, as assessed by TSH, and future risk of venous
thromboembolism: the Tromsø study. Eur J Endocrinol. 2015;173(1):83–90.
https://doi.org/10.1530/EJE-15-0185.
49. Debeij J, van Zaane B, Dekkers OM, Doggen CJM, Smit JWA, van Zanten AP,
et al. High levels of procoagulant factors mediate the association between
free thyroxine and the risk of venous thrombosis: the MEGA study. J
Thromb Haemost. 2014;12(6):839–46. https://doi.org/10.1111/jth.12573.
50. Debeij J, Dekkers OM, Asvold BO, Christiansen SC, Naess IA, Hammerstrom J,
et al. Increased levels of free thyroxine and risk of venous thrombosis in a
large population-based prospective study. J Thromb Haemost. 2012;10(8):
1539–46. https://doi.org/10.1111/j.1538-7836.2012.04818.x.
51. Van Zaane B, Squizzato A, Huijgen R, Van Zanten AP, Fliers E, Cannegieter
SC, et al. Increasing levels of free thyroxine as a risk factor for a first venous
thrombosis: a case-control study. Blood. 2010;115(22):4344–9. https://doi.
org/10.1182/blood-2009-11-253724.
52. Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a
casual or causal association? A systematic literature review. Clin Appl
Thromb. 2011;17(4):387–92. https://doi.org/10.1177/1076029610364521.
53. Debeij J, Cannegieter SC, van Zaane B, van Zanten AP, Rosendaal FR, Gerdes
VEA, et al. Major Haemorrhage during vitamin K antagonist treatment: the
influence of thyroid hormone levels. Eur Thyroid J. 2014;3(1):32–7. https://
doi.org/10.1159/000357578.
54. Manfredi E, Van Zaane B, Gerdes VEA, Brandjes DPM, Squizzato A.
Hypothyroidism and acquired von Willebrand’s syndrome: a systematic
review. Haemophilia. 2008;14(3):423–33. https://doi.org/10.1111/j.1365-251
6.2007.01642.x.
55. Stuijver DJF, Piantanida E, Van Zaane B, Galli L, Romualdi E, Tanda ML, et al.
Acquired von Willebrand syndrome in patients with overt hypothyroidism: a
prospective cohort study. Haemophilia. 2014;20(3):326–32. https://doi.org/1
0.1111/hae.12275.
56. Laurberg P, Knudsen N, Andersen S, Carlé A, Pedersen IB, Karmisholt J.
Thyroid function and obesity. Eur Thyroid J. 2012;1(3):159–67. https://doi.
org/10.1159/000342994.
57. Andersen SL, Andersen S, Liew Z, Vestergaard P, Lundbye-Christensen S,
Sørensen TIA, et al. Maternal thyroid disease and adiposity in mother and
child. Clin Endocrinol. 2020;96:1–10.
58. Carle A, Bulow Pedersen I, Knudsen N, Perrild H, Ovesen L, Banke
Rasmussen L, et al. Smoking cessation is followed by a sharp but
transient rise in the incidence of overt autoimmune hypothyroidism -
a population-based, case-control study. Clin Endocrinol (Oxf). 2012;77:
764–72.
59. Andersen SL, Olsen J, Wu CS, Laurberg P. Smoking reduces the risk of
hypothyroidism and increases the risk of hyperthyroidism: evidence from
450,842 mothers giving birth in Denmark. Clin Endocrinol. 2014;80(2):307–
14. https://doi.org/10.1111/cen.12279.
60. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease.
Front Neuroendocrinol. 2014;35(3):347–69. https://doi.org/10.1016/j.yfrne.2
014.04.004.
61. Weetman AP. Diseases associated with thyroid autoimmunity: explanations
for the expanding spectrum. Clin Endocrinol (Oxf). 2011;74:411–8.
62. Chaturvedi S, McCrae KR. Diagnosis and management of the
antiphospholipid syndrome. Blood Rev. 2017;31(6):406–17. https://doi.org/1
0.1016/j.blre.2017.07.006.
63. Goldman BG, Hehir MP, Yambasu S, O’Donnell EM. The presentation and
management of platelet disorders in pregnancy. Eur J Haematol. 2018;
100(6):560–6. https://doi.org/10.1111/ejh.13049.
64. Shih C-H, Chen S-L, Yen C-C, Huang Y-H, Chen C-D, Lee Y-S, et al. Thyroid
hormone receptor-dependent transcriptional regulation of fibrinogen and
coagulation proteins. Endocrinology. 2004;145(6):2804–14. https://doi.org/1
0.1210/en.2003-1372.
65. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive
health. Endocr Rev. 2010;31(5):702–55. https://doi.org/10.1210/er.2009-0041.
66. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO.
VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic
therapy and prevention of thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):
e691S–736S. https://doi.org/10.1378/chest.11-2300.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Andersen et al. Thyroid Research           (2021) 14:12 Page 10 of 10
